Successful bone marrow transplantation with a matched unrelated donor in an acute promyelocytic leukemia patient after reinduction therapy with arsenic trioxide

Toyotaka Iguchi, Kenji Yokoyama, Keisuke Miyamoto, Yoshinobu Aisa, Takayuki Shimizu, Takehiko Mori, Yasuo Ikeda, Shinichiro Okamoto

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

A 44-year-old man with relapsed acute promyelocytic leukemia (APL), refractory to all-trans-retinoic acid (ATRA), daunorubicin, and cytosine arabinoside, was treated with arsenic trioxide (ATO). ATO was given intravenously at a dose of 0.15 mg/kg/day for 20 days, and the patient achieved complete remission. No serious adverse events related to ATO infusion were observed. He received ATO for 10 days as consolidation therapy and subsequently underwent HLA-matched unrelated donor stem cell transplantation. He remains in molecular remission 10 months after transplant. This case suggests that ATO could be a useful therapy prior to allogeneic stem cell transplantation in relapsed APL.

Original languageEnglish
Pages (from-to)75-77
Number of pages3
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume45
Issue number1
Publication statusPublished - 2004 Jan

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Successful bone marrow transplantation with a matched unrelated donor in an acute promyelocytic leukemia patient after reinduction therapy with arsenic trioxide'. Together they form a unique fingerprint.

Cite this